Biotech Market Banking on Big Cannabis Returns
NEW YORK, December 19, 2017 /PRNewswire/ --
Relatively insulated from economic cycles, the innovation of today's biotech companies puts them in a position to potentially deliver outsized returns regardless of overall conditions. Medicinal
cannabis, a key sector in this industry, is currently driving the largest returns, and it is on pace to exceed US$50 billion in revenues by 2025. As more investors
are noticing, positive news continues to flow into the sector in terms of new drug applications, product approvals and pipeline updates. For InMed Pharmaceuticals, Inc. (CSE: IN) (OTC:
IMLFF) (IMLFF Profile), a preclinical-stage biopharmaceutical company at the vanguard of cannabinoid-based bio-pharmacology, market awareness of the company's drug development pipeline and
biosynthesis technology has led to gains of more than 400% over the last year. This level of activity places InMed, currently valued at $100 million, among the ranks
of larger cannabis biotechs like GW Pharma (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Cara Therapeutics, Inc. (NASDAQ: CARA) and Isodiol
International Inc. (CSE: ISOL) (OTC: ISOLF).
Backed by mounting scientific data on the curative effects of CBDs, specialty biotech companies have the opportunity to capitalize on the explosive growth expected in the cannabis-derived
pharmaceutical market. The discovery of the human endocannabinoid system dramatically changed both the understanding and the vast potential of cannabinoid therapeutics, and thus has increased
acceptance and awareness of the potential of cannabinoids to affect a much broader range of physiological functions than previously considered. With a tsunami of innovation, cannabinoid
pharmaceutical companies now research, identify and develop new drug candidates to create unique therapeutics to treat multiple maladies and unmet medical needs.
InMed Pharmaceuticals, Inc.'s (CSE: IN) (OTCQB: IMLFF) market traction is based on the company's proprietary cannabinoid biosynthesis technology, one of three of its core assets and one which serves as the base for its development of its drug-development pipeline of novel therapeutics that leverage the pharmacological benefits of cannabinoids like CBD. As TheSeedInvestor.com asked in a recent article, could InMed be the "next big thing in cannabis?" (http://cnw.fm/JS9lv).